Private Capital (Trades, Portfolio)'s  Gregg Powers sold the following stocks during the second quarter:
The firm's Cabela's Inc. (CAB, Financial) position was closed with an impact of -2.49% on the portfolio.
The specialty retailer sells hunting, fishing and outdoor gear.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. While the return on equity (ROE) of 6.68% is outperforming the sector, the return on assets (ROA) of 1.53% is underperforming 61% of companies in the Global Specialty Retail industry. Financial strength has a rating of 4 out of 10. The cash-debt ratio of 0.04 is below the industry median of 0.95.
The company's largest shareholder among the gurus is Michael Price (Trades, Portfolio) with 0.75% of outstanding shares, followed by Mario Gabelli (Trades, Portfolio) with 0.32%, Jim Simons (Trades, Portfolio) with 0.17%, George Soros (Trades, Portfolio) with 0.03% and Murray Stahl (Trades, Portfolio) with 0.01%.
The firm exited its holding of Willis Towers Watson PLC (WLTW, Financial). The trade had an impact of -1.32% on the portfolio.
The insurance broker designs and delivers solutions that manage risk, optimize benefits and expand the power of capital to protect institutions and individuals.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The ROE of 4.64% and ROA of 1.53% are underperforming 52% of companies in the Global Insurance Brokers industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.20 is far below the industry median of 1,845.25.
Jeff Ubben (Trades, Portfolio) is the company's largest shareholder among the gurus with 4.92% of outstanding shares, followed by David Herro (Trades, Portfolio) with 3.3%, First Eagle Investment (Trades, Portfolio) with 2.95%, Barrow, Hanley, Mewhinney & Strauss with 1.49% and Richard Pzena (Trades, Portfolio) with 0.99%.
The firm closed its American Public Education Inc. (APEI, Financial) position, impacting the portfolio by -0.86%.
The company provides postsecondary education to individuals through online courses or classroom settings.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The ROE of 5.89% and ROA of 4.88% are outperforming 55% of companies in the Global Education and Training Services industry. Financial strength has a rating of 10 out of 10 with no debt.
With 5.18% of outstanding shares, Simons is the company's largest guru shareholder, followed by Chuck Royce (Trades, Portfolio) with 0.71%, Barrow, Hanley, Mewhinney & Strauss with 0.47% and Paul Tudor Jones (Trades, Portfolio) with 0.07%.
The firm divested of its Valeant Pharmaceuticals International Inc. (VRX, Financial) holding. The transaction had an impact of -0.82% on the portfolio.
The specialty pharmaceutical and medical device company manufactures various treatments for the dermatology, gastrointestinal and ophthalmology markets.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The ROE of -27.72% and ROA of -2.56% are outperforming 84% of companies in the Global Drug Manufacturers - Specialty and Generic industry. Financial strength has a rating of 3 out of 10. The cash-debt ratio of 0.04 is below the industry median of 2.05.
The company's largest shareholder among the gurus is Joel Greenblatt (Trades, Portfolio) with 0.24% of outstanding shares, followed by Ray Dalio (Trades, Portfolio) with 0.02%, Robert Bruce (Trades, Portfolio) with 0.17%, First Eagle Investment with 0.16%, Steven Cohen (Trades, Portfolio) with 0.01% and Diamond Hill Capital (Trades, Portfolio) with 0.01%.
The firm's Charter Financial Corp. (CHFN, Financial) holding was reduced 20.48%. The transaction had an impact of -0.61% on the portfolio.
Charter Financial is the parent company of CharterBank, which offers banking services through its 15 branches in Georgia, Alabama and Florida.
GuruFocus gives the company a profitability and growth rating of 6 out of 10. While the ROE of 7.62% is underperforming the sector, the ROA of 1.08% is outperforming 56% of companies in the Global Banks - Regional - U.S. industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 2.26 is above the industry median of 2.09.
With 6.19% of outstanding shares, Simons is the company's largest guru shareholder, followed by Private Capital with 5.18%.
The firm closed its position in Triumph Group Inc. (TGI, Financial). The transaction had an impact of -0.46% on the portfolio.
The aerospace and defense company manufactures aerostructures, aircraft components and systems.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The ROE of -7.05% and ROA of -1.39% are outperforming 81% of companies in the Global Aerospace and Defense industry. Financial strength has a rating of 4 out of 10. The cash-debt ratio of 0.03 is below the industry median of 0.54.
The company's largest guru shareholder is Richard Snow (Trades, Portfolio) with 1.58% of outstanding shares, followed by Simons with 0.78%, Greenblatt with 0.32% and Barrow, Hanley, Mewhinney & Strauss with 0.32%.
The firm reduced its holding of Celanese Corp. (CE, Financial) by 13.42%. The trade had an impact of -0.35% on the portfolio.
The chemical company produces acetyl, cellulose derivatives and specialty polymers.
GuruFocus gives the company a profitability and growth rating of 5 out of 10. The ROE of 31.65% and ROA of 9.83% are outperforming 77% of companies in the Global Chemicals industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.16 is below the industry median 0.76.
Dodge & Cox is the company's largest shareholder among the gurus with 8.55% of outstanding shares, followed by Barrow, Hanley, Mewhinney & Strauss with 1.38%, Pioneer Investments (Trades, Portfolio) with 0.59%, Columbia Wanger (Trades, Portfolio) with 0.53%, Simons with 0.31% and Cohen with 0.19%.
The firm's Allergan PLC (AGN, Financial) position was reduced by 2.48%, impacting the portfolio by -0.14%.
The pharmaceutical company develops and produces branded and generic drugs.
GuruFocus gives the company a profitability and growth rating of 6 out of 10. The ROE of 14.82% and ROA of 9.08% are outperforming 74% of the companies in the Global Drug Manufacturers - Specialty and Generic industry. Financial strength has a rating of 4 out of 10. The cash-debt ratio of 0.19 is below the industry median of 2.05.
The company's largest guru shareholder is the Vanguard Health Care Fund (Trades, Portfolio) with 3.42% of outstanding shares, followed by John Paulson (Trades, Portfolio) with 0.81%, David Tepper (Trades, Portfolio) with 0.75%, Seth Klarman (Trades, Portfolio) with 0.73%, Spiros Segalas (Trades, Portfolio) with 0.63%, John Griffin (Trades, Portfolio) with 0.43% and Pioneer Investments with 0.4%.
Disclosure: I do not own any shares of any stocks mentioned in this article.
